H. Robin Heyman - Concepedia

Author

H. Robin Heyman

Abbott Fund

Also Known As

H. Heyman, H. R. HEYMAN, H. Robin Heyman, H.R. Heyman, H.Robin Heyman, Heyman, Howard R., Howard R. Heyman

Publications

825

Citations

H-Index

Concepts

All Affiliations

Abbott Fund Abbott (United Kingdom)Abbott (United States)Immunosciences Lab (United States)AbbVie (United States)

About

H. Robin Heyman is an author at Abbott Fund specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	686
2	Biochemistry	11	11	573
3	Natural Sciences	10	10	484
4	Chemical Biology	4	4	123
5	Cell Biology	1	1	30

H. Robin Heyman

Publications

748

Citations

H-Index

Page 1

	Year	Citations
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC) Michael L. Curtin, Robert B. Garland, H. Robin Heyman, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistrySuccinimide Hydroxamic AcidsBiochemistryNatural SciencesMedicine	2002	113
Phenoxyphenyl Sulfone<i>N</i>-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors Carol K. Wada, James H. Holms, Michael L. Curtin, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceChemoprevention StrategyBiochemistryMedicine	2001	102
Differential protein acetylation induced by novel histone deacetylase inhibitors Keith B. Glaser, J. Li, Lori J. Pease, Biochemical and Biophysical Research Communications Histone ModificationsChromatinBiochemistryChromatin RemodelingDifferential Protein Acetylation	2004	67
N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist Steven K. Davidsen, James B. Summers, Daniel H. Albert, Journal of Medicinal Chemistry Soluble ProdrugsPharmaceutical ScienceBiochemistryBlood PlateletMedicine	1994	54
Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors Michael R. Michaelides, Joseph F. Dellaria, Jane Gong, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesPharmacotherapy	2001	52
Heterocyclic ketones as inhibitors of histone deacetylase Anil Vasudevan, Zhiqin Ji, Robin R. Frey, Bioorganic & Medicinal Chemistry Letters Histone ModificationsChromatinMedicinal ChemistryHeterocyclicBiochemistry	2003	52
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors Douglas H. Steinman, Michael L. Curtin, Robert B. Garland, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBiochemistryMedicineNatural Sciences	1998	38
Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists Michael L. Curtin, Steven K. Davidsen, H. Robin Heyman, Journal of Medicinal Chemistry Second-generation Platelet-activating FactorPharmacotherapyPharmaceutical ChemistryInflammationThrombosis	1998	34
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist Daniel H. Albert, Terrance J. Magoc, Paul Tapang, European Journal of Pharmacology InflammationThrombosisThrombopoiesisBlood PlateletMedicine	1997	32
Isoindolinone ureas: a novel class of KDR kinase inhibitors Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryUrologyKdr Kinase InhibitorsMedicineNatural Sciences	2004	32

Page 1